ACUTAAS Acutaas Chemicals Q2 FY26 results (Jul–Sep 2025) and concall
Acutaas Chemicals reported strong Q2 FY26 results with significant revenue and profit growth, primarily driven by its Advanced Pharmaceutical Intermediates segment and CDMO business. The company is on track to achieve its full-year revenue and margin guidance, while also making progress on new growth verticals like battery chemicals and semiconductor chemicals through strategic capex and joint ventures.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|
| Revenue | 271 | 304 | 206 | 305 |
| EBITDA | 67 | 84 | 51 | 97 |
| Net profit | 45 | 63 | 45 | 73 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
